| Status | In progress |
| Process | STA 2018 |
| ID number | 1640 |
Provisional Schedule
| Committee meeting: 1 | 12 November 2020 |
Project Team
| Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email TACommB@nice.org.uk
Consultees
| Companies sponsors | AstraZeneca (olaparib) |
| Others | Department of Health and Social Care |
| NHS Darlington CCG | |
| NHS Wyre Forest CCG | |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Black Health Agency |
| Bob Champion Cancer Trust | |
| Cancer Black Care | |
| Cancer Equality | |
| Helen Rollason Cancer Charity | |
| Independent Cancer Patients Voice | |
| Macmillan Cancer Support | |
| Maggie’s Centres | |
| Marie Curie | |
| Muslim Council of Britain | |
| Orchid | |
| PCaSO - Prostate Cancer Support Organisation | |
| Pelican Cancer Foundation | |
| Prostate Cancer UK | |
| Prostate Help Association | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Tackle Prostate Cancer | |
| Tenovus Cancer Care | |
| Professional groups | Association of Anaesthetists |
| Association of Cancer Physicians | |
| Association of Surgeons of Great Britain and Ireland | |
| British Association of Urological Nurses | |
| British Association of Urological Surgeons | |
| British Geriatrics Society | |
| British Institute of Radiology | |
| British Prostate Group | |
| British Psychosocial Oncology Society | |
| British Uro-Oncology Group | |
| Cancer Research UK | |
| Prostate Cancer Advisory group | |
| Royal College of Anaesthetists | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Royal College of Surgeons | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society and College of Radiographers | |
| UK Clinical Pharmacy Association | |
| UK Health Forum | |
| UK Oncology Nursing Society | |
| Urology Foundation |
Commentators
| Comparator companies | Accord (docetaxel) |
| Bayer (radium-223 dichloride) | |
| Hospira (docetaxel) | |
| Sanofi (cabazitaxel) | |
| Seacross (docetaxel) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| NHS Alliance | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Cochrane Urology |
| Genomics England | |
| Institute of Cancer Research | |
| MRC Clinical Trials Unit | |
| National Cancer Research Institute | |
| National Cancer Research Network | |
| National Institute for Health Research | |
| Ovarian & Prostate Cancer Research Trust | |
| Pro Cancer Research Fund | |
| Prostate Cancer Research Centre |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 March 2020 | Invitation to participate |
| 10 January 2020 - 31 January 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 18 December 2019 | In progress, Referred December 5 2017 |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance